Print Page | Close Window

Press Releases

Keyword Search
2019 | 2018 | 2017 | 2016 | 2015 | 2014
03/21/19Alkermes Statement on National Academies of Sciences, Engineering, and Medicine Report on Medications for Opioid Use DisorderPrinter Friendly Version
03/05/19Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care ConferencePrinter Friendly Version
02/26/19Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid TumorsPrinter Friendly Version
02/25/19Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple SclerosisPrinter Friendly Version
02/20/19Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare ConferencePrinter Friendly Version
02/19/19Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer TherapiesPrinter Friendly Version
02/14/19Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019Printer Friendly Version
02/07/19Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial ResultsPrinter Friendly Version
02/01/19Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug ApplicationPrinter Friendly Version
01/16/19Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) ProgramPrinter Friendly Version
01/02/19Alkermes' Corporate Presentation to be Webcast at the 37th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version